Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Details of the presentations are as follows:
Poster Number: 573
Abstract Number: 2257506
Title: Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities
Date:
Time:
Session Type: Therapeutic Approaches to Autoimmunity (THER)
Session Title: Therapeutics for Autoimmune Diseases I
Location: Exhibit Hall
Presenter: Jonathan Kibel and
Poster Number: 193
Abstract Number: 2253997
Title: EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model
Date:
Time:
Session Type: Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
Session Title: Airway Hypersensitivity and Asthma
Location: Exhibit Hall
Presenter: Yaohui Nie, Ph.D.
Poster Number: 194
Abstract Number: 2257118
Title: Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases
Date:
Time: 2:30 –
Session Type: Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
Session Title: Airway Hypersensitivity and Asthma
Location: Exhibit Hall
Presenter: Joyce Sweeney Gibbons, Ph.D.
Poster Number: 723
Abstract Number: 2257175
Title: Potent STAT6 Inhibitor EPS-3903 Demonstrates Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition following Once-Daily Oral Dosing in Humans
Date
Time:
Session Type: Therapeutic Approaches to Autoimmunity (THER)
Session Title: Therapeutics for Autoimmune Diseases I
Location: Exhibit Hall
Presenter: Daniel Leonard and
Further information about IMMUNOLOGY2026TM can be found here. Posters will be available on the Company’s website here following each presentation.
About
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20260316632112/en/
Media and Investors Contact:
617-744-3848
jviera@enanta.com
Source:
